Dottikon Es Holding AG
SIX:DESN

Watchlist Manager
Dottikon Es Holding AG Logo
Dottikon Es Holding AG
SIX:DESN
Watchlist
Price: 347.5 CHF -0.71% Market Closed
Market Cap: 4.9B CHF

DESN's latest stock split occurred on Mar 2, 2021

The company executed a 932-for-919 stock split, meaning that for every 919 shares held, investors received 932 new shares.

Before the split, DESN traded at 188.9999 per share. Afterward, the share price was about 188.

The adjusted shares began trading on Mar 2, 2021. This was DESN's 2nd stock split, following the previous one in Dec 4, 2020.

Last Splits:
Mar 2, 2021
932-for-919
Dec 4, 2020
10-for-1
Pre-Split Price
186.3636 188.9999
Post-Split Price
188
Before
After
Last Splits:
Mar 2, 2021
932-for-919
Dec 4, 2020
10-for-1

Dottikon Es Holding AG
Stock Splits History

DESN Stock Splits Timeline
Mar 2, 2021
Mar 2, 2021
Split 932-for-919
x1.0141458106638
Pre-Split Price
186.3636 188.9999
Post-Split Price
188
Before
After
Dec 4, 2020
Dec 4, 2020
Split 10-for-1
x10
Pre-Split Price
190.3078 1 929.999
Post-Split Price
207.0707
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
47.5 47.5 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60.6 60.6 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Dottikon Es Holding AG
Glance View

Market Cap
4.8B CHF
Industry
Chemicals

Dottikon Es Holding AG stands as one of Switzerland's understated gems in the realm of fine chemicals and pharmaceuticals. Born from Switzerland's rich tradition of precision and quality, the company operates primarily in the realm of exclusive synthesis, tailored to meet the stringent demands of the pharmaceuticals industry. At its core, Dottikon specializes in hazardous chemical reactions, priding itself on an ability to transform complex chemical processes into high-quality results. This specialization provides a competitive edge, allowing Dottikon to focus on developing innovative and complex molecules which serve as active pharmaceutical ingredients (APIs). It's a business model that not only underscores the company's technical expertise but also its commitment to safety and environmental stewardship, given the heightened risks associated with hazardous materials. Revenue for Dottikon is chiefly generated from strategic partnerships with major pharmaceutical companies. By offering a unique combination of research and development capabilities coupled with state-of-the-art production facilities, Dottikon caters to bespoke needs, from initial developmental scales to full-fledged commercial production runs. The trust and collaboration between Dottikon and its clients are pivotal, as the company becomes an indispensable partner in the clients’ supply chain. As the pharmaceutical sector continues to evolve and demand for specialized molecules increases, Dottikon’s focus on exclusivity and expertise positions it well within the industry, ensuring steady demand and solidifying its role as a reliable, albeit lesser-known, catalyst in advancing pharmaceutical innovations.

DESN Intrinsic Value
235.1 CHF
Overvaluation 32%
Intrinsic Value
Price
Back to Top